Canada markets close in 5 hours 56 minutes

NervGen Pharma Corp. (NGEN.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
1.9900+0.0800 (+4.19%)
As of 09:56AM EST. Market open.
Full screen
Previous Close1.9100
Open1.9500
Bid1.9600 x 0
Ask2.0000 x 0
Day's Range1.9500 - 1.9900
52 Week Range1.5000 - 2.6700
Volume4,550
Avg. Volume17,764
Market Cap116.771M
Beta (5Y Monthly)1.57
PE Ratio (TTM)N/A
EPS (TTM)-0.3680
Earnings DateFeb 27, 2023 - Mar 03, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.25
  • Newsfile

    NervGen Pharma Announces Composition of Matter Patent for NVG-291 Granted by the US Patent and Trade Office

    Vancouver, British Columbia--(Newsfile Corp. - November 17, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that the US Patent and Trade Office (USPTO) has issued US Patent No. 11,497,812 B2 Compositions and Methods for Inhibiting the Activity of LAR Family Phosphatases to Case Western Reserve University. NervGen has an exclusi

  • Newsfile

    NervGen Pharma Grants Stock Options

    Vancouver, British Columbia--(Newsfile Corp. - November 15, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that the Company has granted 400,000 incentive stock options to directors of the Company exercisable at a price of $1.74 per share for a period of five years and that vest equally every three months over ...

  • Newsfile

    NervGen Pharma Completes Dosing in Its Third Multiple Ascending Dose Cohort in Phase 1 Clinical Trial of NVG-291 and Reports Q3 2022 Results

    Dosing completed in third dose cohort of multiple ascending dose (MAD) portion of Phase 1 clinical trial in postmenopausal femalesU.S. Food and Drug Administration (FDA) amendment of partial clinical hold allows for bridging cohorts of males and premenopausal females in the Phase 1 trial to commenceGlenn Ives appointed as Lead Independent DirectorVancouver, British Columbia--(Newsfile Corp. - November 14, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a cl